The involvement of the ADAM proteinases, in particular ADAM10 and -17 (a.k.a. TNF-α converting enzyme, TACE) in the release of pro-inflammatory cytokines such as TNF-α and IL-6 has rendered the ADAMs prime targets for drug discovery in arthritis and cancers [5, 6]. This evidence concerns the gene ADAM17 and cancer.